{"filing":{"accession_number":"0001104659-26-071814","cik":"0001434868","ticker":"ESPR","company_name":"Esperion Therapeutics, Inc.","form":"8-K","filing_date":"2026-06-09","report_date":null,"primary_document":"tm2617356d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1434868/000110465926071814/tm2617356d1_8k.htm"},"events":[{"id":4348,"run_id":3801,"accession_number":"0001104659-26-071814","anchor_item_number":"8.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"summary":"The filing discloses a material update on a pending merger: Esperion entered into a Merger Agreement with ArchiMed SAS affiliates on May 1, 2026, and on June 8, 2026, received clearance from the German antitrust authority (Bundeskartellamt). The disclosure explicitly states the Merger remains subject to HSR clearance and stockholder approval at a special meeting scheduled for July 8, 2026. This is a significant M\u0026A milestone that would materially affect investor assessment of the company's future.","company_name":"Esperion Therapeutics, Inc.","ticker":"ESPR","filing_date":"2026-06-09","items":[{"id":5470,"accession_number":"0001104659-26-071814","item_number":"8.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"The filing discloses a material update on a pending merger: Esperion entered into a Merger Agreement with ArchiMed SAS affiliates on May 1, 2026, and on June 8, 2026, received clearance from the German antitrust authority (Bundeskartellamt). The disclosure explicitly states the Merger remains subject to HSR clearance and stockholder approval at a special meeting scheduled for July 8, 2026. This is a significant M\u0026A milestone that would materially affect investor assessment of the company's future.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-09T20:02:07.082914+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":5470,"accession_number":"0001104659-26-071814","item_number":"8.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"The filing discloses a material update on a pending merger: Esperion entered into a Merger Agreement with ArchiMed SAS affiliates on May 1, 2026, and on June 8, 2026, received clearance from the German antitrust authority (Bundeskartellamt). The disclosure explicitly states the Merger remains subject to HSR clearance and stockholder approval at a special meeting scheduled for July 8, 2026. This is a significant M\u0026A milestone that would materially affect investor assessment of the company's future.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-09T20:02:07.082914+00:00","company_name":"Esperion Therapeutics, Inc.","ticker":"ESPR","filing_date":"2026-06-09"}]}